Caxton Associates (New York)’s Coherus Oncology, Inc. Common Stock CHRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-89,473
| Closed | -$335K | – | 470 |
|
|
2023
Q3 | $335K | Buy |
+89,473
| New | +$335K | 0.05% | 293 |
|
|
2023
Q2 | – | Sell |
-112,186
| Closed | -$767K | – | 523 |
|
|
2023
Q1 | $767K | Buy |
+112,186
| New | +$767K | 0.12% | 191 |
|
|
2022
Q3 | – | Sell |
-12,892
| Closed | -$93K | – | 483 |
|
|
2022
Q2 | $93K | Buy |
+12,892
| New | +$93K | 0.01% | 499 |
|
|
2020
Q2 | – | Sell |
-11,857
| Closed | -$192K | – | 461 |
|
|
2020
Q1 | $192K | Sell |
11,857
-7,000
| -37% | -$113K | 0.04% | 350 |
|
|
2019
Q4 | $340K | Buy |
+18,857
| New | +$340K | 0.05% | 242 |
|